Health Sciences Acquisitions Corporation 2 (HSAQ): Price and Financial Metrics
GET POWR RATINGS... FREE!
HSAQ Stock Price Chart Interactive Chart >
HSAQ Price/Volume Stats
| Current price | $13.31 | 52-week high | $13.80 |
| Prev. close | $10.63 | 52-week low | $9.41 |
| Day low | $10.44 | Volume | 119,600 |
| Day high | $13.50 | Avg. volume | 205,918 |
| 50-day MA | $10.07 | Dividend yield | N/A |
| 200-day MA | $9.96 | Market Cap | 149.23M |
Health Sciences Acquisitions Corporation 2 (HSAQ) Company Bio
Health Sciences Acquisitions Corporation 2 intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.
Latest HSAQ News From Around the Web
Below are the latest news stories about HEALTH SCIENCES ACQUISITIONS CORP 2 that investors may wish to consider to help them evaluate HSAQ as an investment opportunity.
Orchestra BioMed™ Announces Presentation of Positive Long-Term Clinical Results from MODERATO II Control Patients Crossover Extension Study of BackBeat CNT™ at TCT 2022Statistically significant mean reductions of 10.3 mmHg in 24-hour ambulatory systolic blood pressure and 11.7 mmHg in ambulatory pulse pressure after 6 months of therapy in control patients who crossed over to BackBeat CNT following completion of the randomized portion of the MODERATO II studyNEW HOPE, Pa., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Orchestra BioMed™, Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through ri |
Orchestra BioMed™ Announces Strategic Collaboration, Closing of $110 Million Private Equity Financing and Plans to List on Nasdaq Through Merger with Health Sciences Acquisitions Corporation 2Strategic collaboration with Medtronic to develop BackBeat Cardiac Neuromodulation Therapy™ as potential integrated hypertension treatment for cardiac pacemaker patients Investors in $110 million Series D financing include Medtronic and Terumo as well as lead investor RTW Investments and founding investor Perceptive Advisors Business combination with Health Sciences Acquisitions Corporation 2 (Nasdaq: HSAQ) (the “Business Combination”); upon closing, the common stock of the combined company is e |
HSAQ Price Returns
| 1-mo | 32.17% |
| 3-mo | 33.77% |
| 6-mo | 34.99% |
| 1-year | 34.85% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 33.37% |
| 2022 | -0.99% |
| 2021 | -21.31% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...